Tenon Medical (TNON) Expected to Announce Earnings on Thursday

Tenon Medical (NASDAQ:TNON) will likely be posting its Q4 2025 results after the market closes on Thursday, March 19th. Analysts expect Tenon Medical to post earnings of ($0.36) per share and revenue of $1.3780 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:30 PM ET.

Tenon Medical Stock Up 8.2%

Shares of Tenon Medical stock opened at $0.87 on Tuesday. Tenon Medical has a 52 week low of $0.64 and a 52 week high of $5.85. The firm’s 50 day moving average is $0.85 and its two-hundred day moving average is $1.05. The firm has a market capitalization of $9.65 million, a P/E ratio of -0.49 and a beta of 1.25.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tenon Medical in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Tenon Medical has an average rating of “Hold” and a consensus target price of $3.00.

Institutional Investors Weigh In On Tenon Medical

Several institutional investors have recently made changes to their positions in TNON. Jane Street Group LLC acquired a new position in shares of Tenon Medical during the 1st quarter worth $29,000. Geode Capital Management LLC increased its holdings in shares of Tenon Medical by 34.6% in the 4th quarter. Geode Capital Management LLC now owns 66,640 shares of the company’s stock valued at $63,000 after purchasing an additional 17,137 shares in the last quarter. Finally, DRW Securities LLC acquired a new stake in shares of Tenon Medical in the fourth quarter valued at about $98,000. 22.74% of the stock is currently owned by hedge funds and other institutional investors.

Tenon Medical Company Profile

Tenon Medical, Inc is a development-stage medical device company focused on the research, development and commercialization of next-generation surgical biologic adhesives and sealants. The company’s proprietary platform is designed to create tissue-compatible adhesives that can serve as alternatives or complements to traditional sutures and staples, with the goal of improving surgical efficiency, reducing postoperative complications and enhancing patient outcomes.

Tenon Medical’s product pipeline centers on protein-based polymer formulations that cross-link in situ to form a flexible, yet durable, bond with native tissue.